股票行情快报：乐心医疗（300562）2月5日主力资金净买入154.37万元

Core Viewpoint - LeXin Medical (300562) shows a slight increase in stock price and mixed capital flow data, indicating potential investor interest and varying market sentiment [1][2]. Financial Performance - For the first three quarters of 2025, LeXin Medical reported a main revenue of 757 million yuan, a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.68 million yuan, reflecting a significant year-on-year increase of 29.99% [2]. - The net profit after deducting non-recurring items was 59.62 million yuan, up by 19.35% year-on-year [2]. - In Q3 2025, the company experienced a decline in quarterly main revenue to 236 million yuan, down 8.53% year-on-year [2]. - The quarterly net profit attributable to shareholders was 23.39 million yuan, showing a substantial increase of 49.2% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 21.55 million yuan, up by 22.64% year-on-year [2]. - The company's debt ratio stands at 30.1%, with investment income of 4.33 million yuan and financial expenses of 2.01 million yuan [2]. - The gross profit margin is reported at 35.59% [2]. Business Overview - LeXin Medical's main business segments include home medical devices, remote health management (RPM), and AI digital chronic disease management [2]. Capital Flow Analysis - On February 5, 2026, the stock closed at 14.7 yuan, with a turnover rate of 2.74% and a trading volume of 44,400 hands, amounting to a total transaction value of 65.25 million yuan [1]. - The capital flow data for February 5 indicates a net inflow of 1.54 million yuan from main funds, accounting for 2.37% of the total transaction value [1]. - Retail investors experienced a net outflow of 2.66 million yuan, representing 4.08% of the total transaction value [1].